A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia

Several tyrosine kinase inhibitors (TKIs) have been developed as targeted therapies to inhibit the oncogenic activity of several tyrosine kinases in chronic myeloid leukemia (CML), acute lymphoid leukemia (ALL), gastrointestinal stromal tumor (GIST), and other diseases. TKIs have significantly impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Honglan, Gang, Dongxu, He, Xiaoyu, Jiang, Songfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772831/
https://www.ncbi.nlm.nih.gov/pubmed/36568202
http://dx.doi.org/10.3389/fonc.2022.1036437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772831/
https://www.ncbi.nlm.nih.gov/pubmed/36568202
http://dx.doi.org/10.3389/fonc.2022.1036437

Ejemplares similares